Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03412786
Recruitment Status : Recruiting
First Posted : January 26, 2018
Last Update Posted : August 1, 2018
Sponsor:
Information provided by (Responsible Party):
Inge Marie Svane, Herlev Hospital

Brief Summary:

In this Phase I study, patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases are treated with the cancer vaccine Bcl-xl_42-CAF09b. The aim of the study is to clarify the safety and toxicity of the vaccine and also the immunological effect.

The vaccine Bcl-xl_42-CAF09b is composed of the peptide Bcl-xl_42 and the adjuvant CAF09b. The B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases. Bcl-xl_42 is a peptide fragment of the full protein and preclinical studies have shown that vaccination with this peptide (Bcl-xl) can activate the immune system and thereby lead to the death of cancer cells. In order to improve the activation of the immune system, adjuvant CAF09b is added; Preclinical studies have shown that special intraperitoneal (IP) injections of CAF09b improve the activation of the immune system.


Condition or disease Intervention/treatment Phase
Prostate Cancer Biological: Bcl-Xl_42-CAF09b vaccine Phase 1

Detailed Description:

Background:

In this Phase I study, patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases are treated with the cancer vaccine Bcl-xl_42-CAF09b. The aim of the study is to clarify the safety and toxicity of the vaccine and also the immunological effect.

Patients included should be on Bicalutamid treatment upon inclusion. The vaccine Bcl-xl_42-CAF09b is composed of the peptide Bcl-xl_42 and the adjuvant CAF09b. The B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases. Bcl-xl_42 is a peptide fragment of the full protein and preclinical studies have shown that vaccination with this peptide (Bcl-xl) can activate the immune system and thereby lead to the death of cancer cells.

In order to improve the activation of the immune system, adjuvant CAF09b is added; Preclinical studies have shown that special intraperitoneal (IP) injections of CAF09b improve the activation of the immune system.

The CAF09 adjuvant has been developed by Statens Serum Institut (SSI). It is a three-component adjuvant system, composed of cationic liposomes (DDA-MMG1) with complex bound synthetic double-stranded RNA (Poly(I:C)2). The adjuvant was developed as a means to induce cytotoxic CD8+ T-cell responses against vaccine antigens and intended for use in vaccines against disease targets such as cancers, human immunodeficiency virus or Hepatitis C virus. The Poly(I:C) component has previously been in clinical studies as a cancer treatment. Poly(I:C) is known for its pyrogenic activity but upon formulation in the cationic liposome system, CAF09, the pyrogenic effect is significantly reduced.

Methods:

20 patients will be included in this phase I trial. 10 patients will be included in arm A and 10 patients in arm B. Arm a will recieve 3 vaccines every second week IM and thereafter 3 vaccines every second week IP. Arm B will first receive 3 vaccines every second week IP and thereafter every second week IM. All 20 patients will recieve 6 vaccines all in all. This is not randomized - the first 10 patients included will be in arm A and the last 10 patients included will be in arm B.

Patients will be followed with clinical controls every second week.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Masking Description: Not a randomized study. The first 10 patients included will be treated in arm A - the last 10 will be treated in arm B.
Primary Purpose: Treatment
Official Title: A Phase I Study of the Bcl-XL_42-CAF09b Vaccine to Test Safety and Immunological Effect in Patients With Prostate Cancer With Lymph Node Metastases
Actual Study Start Date : May 1, 2018
Estimated Primary Completion Date : February 1, 2020
Estimated Study Completion Date : February 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Arm A: IM followed by IP
Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
Biological: Bcl-Xl_42-CAF09b vaccine
The vaccine consists of 0.05 mg peptide (bcl-xl_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion

Experimental: Arm B: IP followed by IM
Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.
Biological: Bcl-Xl_42-CAF09b vaccine
The vaccine consists of 0.05 mg peptide (bcl-xl_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion




Primary Outcome Measures :
  1. Number and type of reported adverse events [ Time Frame: 0-30 weeks ]
    Determine the safety of the Bcl-XL_42-CAF09b vaccine for patients with prostate cancer with lymph node involvement who are on Bicalutamid treatment by reporting adverse events according to CTCAE v. 4.0


Secondary Outcome Measures :
  1. Treatment related immune responses [ Time Frame: Up to 24 months ]
    To evaluate the immunological impact of the treatment in both arm A and arm B. Elispot and tetramer staining methods will be Applied to identify Bcl-XL_42 peptide specific T cells in the blood over time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Histologically Verified Adenocarcinoma Prostatae
  3. Diagnostic and / or histologically verified lymph node metastases
  4. ECOG Performance Status ≤2
  5. Primary anti-androgen treatment started
  6. Adequate haematological, renal and hepatic function:

    1. Neutrophil granulocytes ≥ 1.5 x 109 / l
    2. Platelet counts ≥ 100 x 109 / l
    3. hemoglobin ≥ 5.6 mmol / l
    4. Serum creatinine ≤ 1.5 times upper normal limit
    5. AST or ALAT ≤ 2.5 times upper normal limit
    6. serum bilirubin ≤ 1.5 times upper normal limit
    7. Alkaline phosphatase ≤ 2.5 times upper normal limit
    8. INR <1.5 / PP <40

Exclusion Criteria:

  1. Verified bone or visceral metastases
  2. Serious allergy or previous anaphylactic reactions
  3. Known hypersensitivity to any of the active substances or to any of the excipients.
  4. Other malignant disease within the last three years, rendering planocellular and basocellular skin carcinoma
  5. Known infection with HIV, hepatitis B and C virus, regardless of whether the infection is kept calm with medical treatment
  6. Severe medical disorder, severe asthma, severe COPD, poorly regulated cardiovascular disease or diabetes
  7. Active autoimmune disease, e.g. autoimmune neutropenia / thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, goodpasture syndrome, Addison's disease, Hashimoto's thyroiditis, active grave disease, morbus chrohn or ulcerative colitis
  8. Major gastrointestinal surgical procedures within the last 3 months
  9. Previous treatment with other cancer vaccine
  10. Concomitant immunosuppressive treatment including prednisolone and methotrexate
  11. Ongoing anticoagulant treatment (treatment with acetylsalicylic acid and clopidogrel is allowed)
  12. Psychiatric disease which, according to the investigator's discretion, may affect compliance
  13. Co-administration with other experimental drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03412786


Locations
Layout table for location information
Denmark
Herlev Hospital Recruiting
Herlev, Denmark, 2730
Contact: Inge Marie Svane, Prof., MD    +4538683868    inge.marie.svane@regionh.dk   
Contact: Julie W Kjeldsen, MD    +4538683868    julie.westerlin.kjeldsen@regionh.dk   
Sponsors and Collaborators
Herlev Hospital

Layout table for additonal information
Responsible Party: Inge Marie Svane, Prof., MD, Herlev Hospital
ClinicalTrials.gov Identifier: NCT03412786     History of Changes
Other Study ID Numbers: UR1534
First Posted: January 26, 2018    Key Record Dates
Last Update Posted: August 1, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs